Therefore, developing specific FABP5 inhibitors, or interfering with the release, transport of exosomal FABP5, or its interaction with TAMs, combined with existing immunotherapies, may offer a synergistic and more effective therapeutic approach for HCC patients, ultimately improving their clinical outcomes. The gene discussed is FABP5; the disease is hepatocellular carcinoma.